As this study suggests an additive effect on QT-prolongation when the “bonding-hormone” oxytocin - which has emerged as promising drug for a variety of psychiatric disorders - is combined with risperidone or fluoxetine, the indication for such a combined treatment should be considered carefully, and ECG / QT duration should be monitored regularly during treatment (particularly in situations in which additional pro-arrhythmic factors are present such as electrolyte imbalances). The gene discussed is OXT; the disease is psychiatric disorder.